Cantargia AB (CANTA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cantargia AB (CANTA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8228
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スウェーデン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cantargia AB (Cantargia), a subsidiary of Lund University Bioscience AB is a biotechnology company that develops antibody based cancer treatments. The company’s product candidate CAN04 is used for the treatment of several cancers including non-small cell lung cancer and pancreatic cancer. It utilizes cell surface receptor as a target to develop a novel antibody based therapy for the treatment of chronic myeloid leukemia and other forms of leukemia. Cantargia provides therapies for the treatment of hematological malignancies that uses the expression of cell surface receptor on hematopoietic stem cells. The company also develops antibody therapeutics to eradicate the leukemia disease causing stem cells. Cantargia is headquartered in Lund, Sweden.

Cantargia AB (CANTA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cantargia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cantargia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cantargia AB, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Cantargia Raises USD3 Million in Venture Financing 11
Cantargia Raises USD0.46 Million in Venture Financing 12
Cantargia Raises US$1 Million In Venture Financing 13
Partnerships 14
Cantargia and Panorama Research Enter into Co-Development Agreement 14
Licensing Agreements 15
Cantargia Enters into Licensing Agreement with BioWa 15
Equity Offering 16
Cantargia Raises USD7.7 Million in Rights Offering of Shares 16
Cantargia Raises USD2.8 Million in Private Placement of Shares upon Exercise of Warrants 17
Cantargia Plans to Raise upto USD12.2 Million 18
Cantargia Raises Funds through Private Placement of Shares upon Exercise of Warrants 19
Cantargia Raises USD4 Million in Private Placement of Shares upon Exercise of Warrants 20
Cantargia to Raise USD0.5 Million in Private Placement of Shares up on Exercise of Warrants 21
Cantargia Raises USD5.13 Million in IPO 22
Cantargia Raises USD0.07 Million in Private Placement of Shares up on Exercise of Warrants 23
Cantargia AB – Key Competitors 24
Cantargia AB – Key Employees 25
Cantargia AB – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 21, 2018: Cantargia publishes 2018 half year report 27
May 15, 2018: Cantargia publishes interim report for first quarter 2018 28
Feb 28, 2018: Cantargia publishes year end report for 2017 29
Nov 08, 2017: Cantargia publishes interim report for third quarter of 2017 30
Aug 23, 2017: Cantargia publishes half year report 31
Mar 15, 2017: Cantargia publishes year-end report for 2016 32
Corporate Communications 33
Sep 25, 2018: Nasdaq Stockholm welcomes Cantargia to the main market 33
Jul 13, 2018: Cantargia approved for listing on Nasdaq Stockholm First North Premier as part of the process towards Nasdaq Stockholm’s main market 34
May 19, 2017: Cantargia strengthens organisation with CFO 35
Product News 36
10/13/2017: Cantargia announces first patient treated and completed a three weeks safety evaluation period with immuno-oncology antibody CAN04 36
07/21/2017: Cantargia Gains Approval to Initiate the CANFOUR Clinical Trial of Immuno-oncology Product Candidate CAN04 37
06/19/2018: Cantargia’s immuno-oncology antibody CAN04 has obtained the INN nidanilimab by WHO 38
05/16/2018: Cantargias immuno-oncology project CAN04 shows promise in additional cancer forms 39
03/15/2018: Cantargia Presents New Data at AACR on Inhibition of Metastasis by Antibodies Against IL1RAP 40
01/05/2017: Cantargia’s research and development to be presented at Biotech Showcase in San Francisco on 9 January 2017 41
Product Approvals 42
May 12, 2017: Cantargia’s Application to Investigate the Antibody Product Candidate CAN04 in the CANFOUR Phase I/IIa Clinical Trial has been Submitted 42
Clinical Trials 43
Apr 16, 2018: Cantargia presents anti-metastatic effect of IL1RAP blocking antibody at AACR 43
Mar 06, 2018: Cantargia: antibody against ILRAP reduce metastases in experimental cancer model 44
Jun 26, 2017: Cantargia: Preclinical studies of IL1RAP and CAN04 in solid tumours presented at EACR-AACR-SIC in Florence 45
May 08, 2017: Cantargia’s product candidate CAN04 shows good safety properties in studies performed under GLP 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Cantargia AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cantargia AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cantargia AB, Deals By Therapy Area, 2012 to YTD 2018 9
Cantargia AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cantargia Raises USD3 Million in Venture Financing 11
Cantargia Raises USD0.46 Million in Venture Financing 12
Cantargia Raises US$1 Million In Venture Financing 13
Cantargia and Panorama Research Enter into Co-Development Agreement 14
Cantargia Enters into Licensing Agreement with BioWa 15
Cantargia Raises USD7.7 Million in Rights Offering of Shares 16
Cantargia Raises USD2.8 Million in Private Placement of Shares upon Exercise of Warrants 17
Cantargia Plans to Raise upto USD12.2 Million 18
Cantargia Raises Funds through Private Placement of Shares upon Exercise of Warrants 19
Cantargia Raises USD4 Million in Private Placement of Shares upon Exercise of Warrants 20
Cantargia to Raise USD0.5 Million in Private Placement of Shares up on Exercise of Warrants 21
Cantargia Raises USD5.13 Million in IPO 22
Cantargia Raises USD0.07 Million in Private Placement of Shares up on Exercise of Warrants 23
Cantargia AB, Key Competitors 24
Cantargia AB, Key Employees 25

List of Figures
Cantargia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cantargia AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cantargia AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cantargia AB (CANTA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Precision Optics Corporation Inc (PEYE):企業の財務・戦略的SWOT分析
    Summary Precision Optics Corporation Inc (Precision Optics) is a medical device company that designs, develops, manufactures and distributes optics and optical systems for medical, biomedical, and industrial applications. The company provides custom optics solutions such as design and prototyping, f …
  • Munchener Ruckversicherungs-Gesellschaft AG (Munich Re):戦略・SWOT・企業財務分析
    Munchener Ruckversicherungs-Gesellschaft AG (Munich Re) - Strategy, SWOT and Corporate Finance Report Summary Munchener Ruckversicherungs-Gesellschaft AG (Munich Re) - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the compan …
  • Oriental Bank of Commerce:企業の戦略・SWOT・財務分析
    Oriental Bank of Commerce - Strategy, SWOT and Corporate Finance Report Summary Oriental Bank of Commerce - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Egyptian Resorts Co:企業の戦略・SWOT・財務分析
    Egyptian Resorts Co - Strategy, SWOT and Corporate Finance Report Summary Egyptian Resorts Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • B&M European Value Retail S.A.:企業の戦略・SWOT・財務情報
    B&M European Value Retail S.A. - Strategy, SWOT and Corporate Finance Report Summary B&M European Value Retail S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Silver Spring Networks, Inc. (SSNI)-エネルギー分野:企業M&A・提携分析
    Summary Silver Spring Networks, Inc. (Silver Spring) is a smart grid networking platform technology and solutions provider. The company’s products include metering devices, network infrastructure, utilityIQ applications, GridScape software and customerIQ web portal. Silver Spring provides wide range …
  • InSphero AG:医療機器:M&Aディール及び事業提携情報
    Summary InSphero AG (InSphero) is a biotechnology company that offers production, culture and assessment of organotypic 3D cell culture models. The company’s product portfolio includes microtissues kits, cytotoxicity assay kits, and microtissue spheroids, among others. Its patented 3D cell culture p …
  • Japan Oil, Gas and Metals National Corp:企業の戦略的SWOT分析
    Japan Oil, Gas and Metals National Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Oriental Land Co., Ltd.:企業の戦略・SWOT・財務分析
    Oriental Land Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Oriental Land Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • SVOGL Oil Gas and Energy Ltd:企業の戦略的SWOT分析
    SVOGL Oil Gas and Energy Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Mead Johnson Nutrition Co:企業の戦略的SWOT分析
    Mead Johnson Nutrition Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • The InterTech Group Inc:企業の戦略的SWOT分析
    The InterTech Group Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products an …
  • Caltex Australia Ltd (CTX)-石油・ガス分野:企業M&A・提携分析
    Summary Caltex Australia Limited (Caltex) is a transport fuel supplier and convenience retailer. It is the parent company of Caltex group. The company purchases, refines, distributes and markets petroleum products. It owns and operates refinery, convenience stores, road tankers, storage terminals, s …
  • HoMedics USA LLC:企業の戦略的SWOT分析
    HoMedics USA LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servi …
  • GenMark Diagnostics Inc (GNMK):企業の財務・戦略的SWOT分析
    Summary GenMark Diagnostics Inc (GenMark) is a medical device company that provides clinical testing systems. The company offers products such as XT-8 systems and ePlex systems. It offers pipeline products include eSensor 2C 19 genotyping test, eSensor HCV genotyping test, eSensor HCVg direct test, …
  • Zynex Inc (ZYXI):企業の財務・戦略的SWOT分析
    Summary Zynex Inc (Zynex) formerly Zynex Medical Inc operates as a medical technology company that designs, manufactures, and markets electrotherapy medical devices used for pain management and rehabilitation. The company’s products include NexWave, a dual channel, multi-modality interferential curr …
  • Yamato Holdings Co., Ltd.:企業の戦略・SWOT・財務分析
    Yamato Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Yamato Holdings Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Skanray Technologies Pvt Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Skanray Technologies Pvt Ltd (Skanray) is a medical equipment manufacturing company. It provides high frequency x-ray imaging systems, critical care devices, and primary healthcare and telemedicine compatible devices. The company’s product categories include defibrillator, ventilators, surgi …
  • Vior Inc (VIO):企業の財務・戦略的SWOT分析
    Summary Vior Inc (Vior) is a mining and mineral exploration company. The company carries out the business of acquisition, exploration, and development of gold and silver metal properties in North and Latin America. Its projects comprise Mosseau Gold project, Foothills Rutile project, Vezza-Noyard Go …
  • R. R. Donnelley & Sons Co (RRD):企業の財務・戦略的SWOT分析
    R. R. Donnelley & Sons Co (RRD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆